dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Park, Keunchil |
dc.contributor.author | Jӓnne, Pasi A. |
dc.contributor.author | Kim, Dong-Wan |
dc.contributor.author | Han, Ji-Youn |
dc.contributor.author | Wu, Ming-Fang |
dc.contributor.author | Lee, Jong-Seok |
dc.contributor.author | Felip Font, Enriqueta |
dc.date.accessioned | 2021-06-21T12:00:52Z |
dc.date.available | 2021-06-21T12:00:52Z |
dc.date.copyright | 2020 |
dc.date.issued | 2021-05-01 |
dc.identifier.citation | Park K, Jӓnne PA, Kim D, Han J, Wu M, Lee J, et al. Olmutinib in T790M‐positive non–small cell lung cancer after failure of first‐line epidermal growth factor receptor‐tyrosine kinase inhibitor therapy: A global, phase 2 study. Cancer. 2021 May 1;127(9):1407-1416. |
dc.identifier.issn | 1097-0142 |
dc.identifier.uri | https://hdl.handle.net/11351/6087 |
dc.description | Receptor del factor de creixement epidèrmic; Càncer de pulmó de cèl·lules no petites; Inhibidor de la tirosina quinasa |
dc.description.sponsorship | Hanmi Pharmaceutical Co. Ltd. |
dc.language.iso | eng |
dc.publisher | Wiley |
dc.relation.ispartofseries | Cancer;127(9) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Pulmons - Càncer - Tractament |
dc.subject | Medicaments antineoplàstics |
dc.subject | Prognosi |
dc.subject.mesh | Carcinoma, Non-Small-Cell Lung |
dc.subject.mesh | Antineoplastic Agents |
dc.subject.mesh | Progression-Free Survival |
dc.title | Olmutinib in T790M-positive non–small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1002/cncr.33385 |
dc.subject.decs | carcinoma de pulmón de células no pequeñas |
dc.subject.decs | antineoplásicos |
dc.subject.decs | supervivencia libre de progresión |
dc.relation.publishversion | https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.33385 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Park K] Division of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. [Jӓnne PA] Lowe Center for Thoracic Oncology, The Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts. [Kim DW] Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea. [Han JY] National Cancer Center, Goyang, Republic of Korea. [Wu MF] Chung Shan Medical University Hospital, Taichung, Taiwan. [Lee JS] Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. [Felip E] Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 33434335 |
dc.identifier.wos | 000606964500001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |